Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 10/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 10/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29347256 | 0.91 | KDM4E (0.45) | DDB1CRBNALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL29347429 | 0.88 | DDB1 (0.48) | DDB1CRBNALDH1A1KDM4EOPRL1 | |
| SCHEMBL29347124 | 0.88 | DDB1 (0.47) | DDB1CRBNALDH1A1KDM4EOPRL1 | |
| SCHEMBL29347427 | 0.84 | DDB1 (0.51) | DDB1CRBNOPRL1OPRM1 | |
| SCHEMBL29347058 | 0.84 | ALDH1A1 (0.44) | ALDH1A1KDM4EL3MBTL1OPRL1OPRM1 | |
| SCHEMBL29347426 | 0.83 | DDB1 (0.51) | DDB1CRBNOPRM1 | |
| SCHEMBL28649449 | 0.82 | DDB1 (0.53) | DDB1CRBNALDH1A1KDM4E | |
| SCHEMBL31730014 | 0.81 | DDB1 (0.50) | DDB1CRBN | |
| SCHEMBL29346456 | 0.80 | DDB1 (0.60) | DDB1CRBNALDH1A1OPRL1OPRM1 | |
| SCHEMBL31729996 | 0.80 | DDB1 (0.58) | DDB1CRBNOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-12-25 | — | — | US | disclosed |
| EP-4650348-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2025-11-19 | — | — | EP | disclosed |
| WO-2024150815-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | 田辺三菱製薬株式会社 | 2024-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | CRBN, CUL1, CBL | DDB1 2368/4885CRBN 1/4885ALDH1A1 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.